A5033285748- Autoimmune Neurological Disorders and Treatments
- Genetics and Neurodevelopmental Disorders
- Peripheral Neuropathies and Disorders
- Cerebrovascular and Carotid Artery Diseases
- Stroke Rehabilitation and Recovery
- Acute Ischemic Stroke Management
- Cellular transport and secretion
- Epilepsy research and treatment
- Neuroinflammation and Neurodegeneration Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Neurological Complications and Syndromes
- RNA and protein synthesis mechanisms
- Chemokine receptors and signaling
- Diabetes and associated disorders
- Glycogen Storage Diseases and Myoclonus
- CNS Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- COVID-19 Clinical Research Studies
- Viral Infections and Vectors
- Mosquito-borne diseases and control
- Travel-related health issues
- Genetic Neurodegenerative Diseases
- Long-Term Effects of COVID-19
- Metabolism and Genetic Disorders
- Infectious Encephalopathies and Encephalitis
Erasmus MC
2016-2025
Odense University Hospital
2024
University of Southern Denmark
2024
University Hospital Bonn
2024
Bielefeld University
2024
Radboud University Nijmegen
2021-2023
Radboud University Medical Center
2021-2023
Canisius-Wilhelmina Ziekenhuis
2023
Maastricht University Medical Centre
2023
Neurology, Inc
2023
Anti-IgLON5 disease is a recently described neurologic that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent important but have not been characterized are underreported. We describe the frequency types movement disorders in series consecutive patients with this disease.In retrospective, observational study, presence phenomenology were assessed standardized clinical questionnaire. Available videos centrally reviewed by 3 experts...
Abstract Anti-Leucine-rich glioma inactivated-1 (LGI1) and anti-contactin-associated-protein-2 (CASPR2) autoimmune encephalitis (AIE) are common characterized by pathogenic antibodies targeting neuronal autoantigens. However, the drivers of antibody-secreting cells (ASC) involvement T remain unresolved. We performed single cell RNA-sequencing fresh cerebrospinal fluid (CSF) parallel blood samples 15 patients with LGI1- (n=9) CASPR2-AIE (n=6) compared to control (multiple sclerosis (MS) n=15,...
<h3>Background and Objectives</h3> To describe the clinical features of anti-NMDAR encephalitis, emphasizing on late-onset patients antibody test characteristics in serum CSF. <h3>Methods</h3> Nationwide observational Dutch cohort study, diagnosed with encephalitis between 2007 2019. <h3>Results</h3> One hundred twenty-six were included a median age 24 years (range 1–86 years). The mean annual incidence was 1.00/million (95% CI 0.62–1.59). Patients ≥45 at onset (19%) had fewer seizures (46%...
Autoimmune encephalitis (AIE) and paraneoplastic neurologic syndromes (PNSs) encompass a heterogeneous group of antibody-associated disorders. Both the number commercially available antibody tests have increased considerably over past decade. High-quality population-based data on epidemiology these disorders real-world performance are needed.
Determinants of disease activity and prognosis are limited in anti-NMDA receptor (NMDAR) encephalitis. Neurofilament light chains (NfL) markers axonal damage have been identified as valuable biomarkers for neurodegenerative other neuroinflammatory disorders. We aimed to investigate serum NfL levels patients with anti-NMDAR encephalitis a biomarker severity outcome.In this retrospective study, values were measured all available pretreatment paired CSF samples the nationwide cohort. The...
<h3>Objective</h3> As autoimmune encephalitis (AIE) can resemble neurodegenerative dementia syndromes, and patients do not always present as encephalitis, this study evaluates how frequently AIE mimics provides red flags for in middle-aged older patients. <h3>Methods</h3> In nationwide observational cohort study, with anti–leucine-rich glioma-inactivated 1 (LGI1), anti–NMDA receptor (NMDAR), anti–gamma-aminobutyric acid B (GABA<sub>B</sub>R), or anti–contactin-associated protein-like 2...
Most patients with encephalitis experience persisting neurocognitive and neuropsychiatric sequelae in the years following this acute illness. Reported outcomes are often based on generic clinical outcome assessments that rarely capture patient perspective. This may result an underestimation of disease-specific sequelae. Disease-specific can improve relevance reported increase power research trials. There no patient-reported measures (PROMs) developed or validated specifically for...
Patients with ongoing seizures are usually not allowed to drive. The prognosis for seizure freedom is favorable in patients autoimmune encephalitis (AIE) antibodies against NMDA receptor (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and the gamma-aminobutyric-acid B (GABA
Anti-NMDA receptor (anti-NMDAR) encephalitis generally manifests in young adults. Although 80%-90% returns to independence, the majority experience persistent cognitive and psychosocial difficulties. Studies have demonstrated that recovery may continue for years; temporal trajectory is largely unknown, as are factors influencing cognitive/psychosocial recovery. Objectives were (1) describe trajectory, (2) assess self-reported outcomes, (3) identify relating outcome, (4) explore relation...
Abstract Objective A substantial part of central nervous system (CNS) disorders remains unexplained, despite various new and minimally invasive diagnostic techniques. Within this rapidly developing field, the precise role brain biopsy is unknown. We aimed to study clinical impact safety biopsies in unexplained CNS disorders. Methods In retrospective cohort study, we included all adult patients who were referred for a work‐up our academic center with neuro‐inflammatory, neuro‐oncological,...
Paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS) have a very poor prognosis: more than half of the patients become bedridden and median survival is less 12 months. Several lines evidence suggest pathogenic T cell-mediated immune response. Therefore, we conducted prospective open-label phase II trial natalizumab.Twenty Hu-PNS progressive disease were treated maximum three monthly natalizumab cycles (300 mg). The primary outcome measure was functional improvement, this...
<h3>Objective:</h3> To investigate the effect of intra-arterial treatment (IAT) on early recovery from aphasia in acute ischemic stroke. We hypothesized that IAT is smaller than motor deficits. <h3>Methods:</h3> included patients with Multicenter Randomized Clinical Trial Endovascular Treatment for Acute Ischemic Stroke Netherlands (MR CLEAN), which 500 a proximal anterior circulation stroke were randomized to usual care plus (<6 hours after stroke, mainly stent retrievers) or alone....
Here, we describe the clinical phenotype of SARS-CoV-2-related CNS disease and evaluate SARS-CoV-2 antibody index as a tool to differentiate between direct (viral) indirect etiology. Out >4000 hospitalized patients with COVID-19, included 13 neurological symptoms suspicion neuroinflammation. On grounds, eight were classified having possible/probable relationship COVID-19. A clinically distinctive brainstem cerebellar was seen in 6/8 patients. As found positive 3/5 patients, indicating...
Introduction: Clinical observations suggest that language deficits in acute ischemic stroke do not respond as rapidly to reperfusion therapy motor deficits. We tested for a differential effect of intra-arterial treatment with retrievable stents on recovery from aphasia and upper limb paresis MR CLEAN. Hypothesis: The early IAT is similar size. Methods: All patients who were randomized CLEAN included. Primary outcomes the score NIH scale item extremity contralateral affected hemisphere,...
Develop and validate a model to predict functional outcome response first-line therapy at the time of diagnosis anti-NMDAR encephalitis (anti-NMDARE).
Nieuw ontstane epilepsie bij kinderen en volwassenen kan wijzen op een auto-immuun oorzaak, met name als de voorkomt in combinatie neuropsychiatrische klachten of therapieresistent blijkt. Het is belangrijk om snel te herkennen omdat klinische uitkomst verbetert naarmate er sneller gestart wordt behandeling. Vanwege variatie mogelijke het stellen van diagnose vaak uitdaging.